Thiazolidinediones

• 

  Subject Areas on Research

  • A futile metabolic cycle activated in adipocytes by antidiabetic agents. 
  • A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. 
  • A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. 
  • Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Axokinin phosphorylation by cAMP-dependent protein kinase is sufficient for activation of sperm flagellar motility. 
  • Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. 
  • Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis. 
  • Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone. 
  • Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. 
  • Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. 
  • Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain. 
  • Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. 
  • Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. 
  • GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. 
  • Hepatic complications of obesity. 
  • Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. 
  • Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. 
  • Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. 
  • Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone. 
  • New applications of disease genetics and pharmacogenetics to drug development. 
  • Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. 
  • Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. 
  • Peroxisome Proliferator-Activated Receptor γ and Its Role in Adipocyte Homeostasis and Thiazolidinedione-Mediated Insulin Sensitization. 
  • Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter. 
  • Physiologic straws in the wind: in which direction do they bend? 
  • Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha. 
  • Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. 
  • Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. 
  • Potential nonhormonal therapeutics for medical treatment of leiomyomas. 
  • Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. 
  • Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). 
  • Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. 
  • Results of a reevaluation of cardiovascular outcomes in the RECORD trial. 
  • Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. 
  • Smooth Muscle Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Formation and Rupture of Cerebral Aneurysms in Mice In Vivo. 
  • Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. 
  • The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. 
  • The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 
  • The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. 
  • Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism. 
  • Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? 
  • Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. 
  • Troglitazone-associated hepatotoxicity treated successfully with steroids. 
  • Type 2 diabetes, thiazolidinediones: bad to the bone? 
  • Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. 
  • Using genetics to enable studies on the prevention of Alzheimer's disease. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology